Omniscan (Gadodiamide)

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to highlight vascular and tissue structures.

• Central nervous system imaging: improves detection of lesions, tumors, and inflammatory lesions.
• Cardiovascular MRI: enhances visualization of cardiac chambers, vessels, and myocardial perfusion.
• Whole‑body and oncologic MRI: aids in identifying metastatic disease and tumor extent.
• MR angiography: provides detailed images of arterial and venous anatomy.
• Joint and musculoskeletal MRI: improves contrast of cartilage, ligaments, and soft‑tissue lesions.

• Gadodiamide is a gadolinium‑based contrast agent that shortens the T1 relaxation time of nearby water protons when administered intravenously. The paramagnetic gadolinium ion creates a local magnetic field disturbance, increasing signal intensity on T1‑weighted MRI sequences and thereby enhancing the visual contrast between vascular structures, extracellular spaces, and surrounding tissues.

Adverse reactions to gadodiamide‑based contrast agents vary in frequency and severity.

Common Side Effects

• Nausea: mild, transient episodes reported.
• Headache: occasional mild discomfort.
• Injection site discomfort: mild pain or warmth at the infusion site.
• Warm sensation: brief feeling of heat during administration.
• Metallic taste: transient metallic sensation in the mouth.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment.
• Anaphylactoid reactions: acute hypersensitivity including rash, bronchospasm, or hypotension.
• Severe allergic reactions: urticaria, angioedema, or anaphylaxis.
• Cardiac arrest: extremely rare, associated with severe hypersensitivity.
• Renal function decline: worsening of pre‑existing kidney disease.
• Death: rare fatal outcomes linked to severe hypersensitivity or NSF.

When using Omniscan, clinicians should assess patient risk factors and monitor for adverse events.

• Renal impairment: evaluate kidney function before administration.
• Pregnancy: avoid use unless clearly needed; discuss risks with obstetric specialist.
• Breastfeeding: consider potential excretion in milk; weigh benefits against risks.
• Allergic history: review prior reactions to contrast media.
• Concomitant nephrotoxic drugs: use with caution.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Gadodiamide may interact with other agents that affect renal function or immune response.

Major Interactions (Avoid)

• Loop diuretics: may exacerbate renal impairment when combined with gadolinium agents.
• High‑dose intravenous iron: can increase risk of hypersensitivity reactions.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal clearance of gadolinium.
• Metformin: monitor for lactic acidosis in patients with reduced kidney function.
• ACE inhibitors/ARBs: may influence renal hemodynamics, requiring observation.
• Radiopharmaceuticals: concurrent use may alter imaging interpretation.
• Other contrast agents: stagger administration to reduce cumulative gadolinium load.